Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14686251 | 0.85 | FFAR1 (0.49) | FFAR1FFAR4PTGDR2KMT2AMEN1 | |
| SCHEMBL31464099 | 0.84 | FFAR1 (0.46) | FFAR1FFAR4PTGDR2KMT2AMEN1 | |
| SCHEMBL759109 | 0.84 | FFAR1 (0.46) | FFAR1FFAR4PTGDR2KMT2AMEN1 | |
| SCHEMBL3746360 | 0.83 | FFAR4 (0.66) | FFAR1FFAR4PTGDR2 | |
| SCHEMBL5200837 | 0.82 | FFAR4 (0.39) | FFAR1FFAR4PTGDR2KMT2AMEN1 | |
| SCHEMBL27718714 | 0.81 | FFAR1 (0.46) | FFAR1FFAR4PTGDR2KMT2AMEN1 | |
| SCHEMBL28238287 | 0.81 | ADORA3 (0.45) | FFAR1FFAR4PTGDR2KMT2AMEN1 | |
| SCHEMBL760901 | 0.80 | FFAR1 (0.47) | FFAR1FFAR4PTGDR2KMT2AMEN1 | |
| SCHEMBL3732787 | 0.80 | FFAR1 (0.43) | FFAR1FFAR4PTGDR2KMT2AMEN1 | |
| SCHEMBL2865401 | 0.79 | TDP1 (0.50) | FFAR1FFAR4KMT2ACSNK2A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817031-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | Merck Patent GmbH (DE) | 2007-08-15 | — | — | EP | claimed |
| WO-2006058592-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | MERCK PATENT GMBH (DE) | 2006-06-08 | — | — | WO | claimed |
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2025-10-23 | — | — | US | disclosed |
| CN-119816484-A | Novel piperazine derivative or salt thereof and pharmaceutical composition | 富士胶片株式会社 | 2025-04-11 | — | — | CN | disclosed |
| WO-2024043334-A1 | NOVEL PIPERAZINE DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION | 富士フイルム株式会社 | 2024-02-29 | — | — | WO | disclosed |
| EP-1817031-B1 | CASPASE-10 INHIBITORS FOR PREVENTION AND TREATMENT OF RETINOPATHY | MERCK PATENT GMBH (DE) | 2014-05-21 | — | — | EP | disclosed |
| US-7829721-B2 | Specific caspase-10 inhibitors | MERCK PATENT GMBH (DE) | 2010-11-09 | — | — | US | disclosed |
| US-20080255173-A1 | Novel Specific Caspase-10 Inhibitors | MERCK PATENT GESELLSCHAFT (DE) | 2008-10-16 | — | — | US | disclosed |
| EP-1817031-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | Merck Patent GmbH (DE) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006058592-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | MERCK PATENT GMBH (DE) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255173-A1 | Novel Specific Caspase-10 Inhibitors | CASP10, CASP1, CASP5 | FFAR1 624/4885FFAR4 860/4885PTGDR2 3995/4885 |
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | ABCB11, ABCC1, SLC11A2 | FFAR1 3148/4885FFAR4 4300/4885PTGDR2 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.